These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20359633)

  • 1. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
    Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
    Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
    Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
    Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
    Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing hypomethylating agents in myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA; Talwar S; Yang AS
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of azacitidine: onset, duration, and treatment.
    Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
    Sekeres MA
    Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.